Author

S. S. Watowich

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:mouse· 4 Research Focus:cell type annotation· 3 Research Focus:host-pathogen & immune response· 3 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1

Frequent Co-Authors

E. M. Park· 2 shared H. Wang· 2 shared Y. Zhou· 2 shared A. Arnett· 1 shared A. M. Dyevoich· 1 shared A. M. Sockwell· 1 shared A. Viale· 1 shared A. Yousef· 1 shared

Activity by Year

2021-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

E. M. Park

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

KRAS inhibition activates an actionable CD24 do-not-eat-me signal in pancreatic cancer

Y. Wei, M. Liu, E.-Y. Yen, J. Yao, Z. Xun, P. T. Nguyen, X. Wang, Z. Yang, A. Yousef, D. Pan, Y. Jin, C.-F. Li, M. S. Theardy, J. Park, Y. Cai, , H. Ying

This study identifies CD24 as an actionable signal activated by KRASG12C inhibition in pancreatic cancer, enhancing macrophage phagocytosis and sensitizing tumors to therapy.

bioRxiv · Sep 21, 2023Cancer Biology

Antigen-presenting type-I conventional dendritic cells facilitate curative checkpoint blockade immunotherapy in pancreatic cancer

K. K. Mahadevan, A. M. Dyevoich, Y. Chen, B. Li, H. Sugimoto, A. M. Sockwell, K. M. McAndrews, H. Wang, S. Shalapour, S. S. Watowich, R. Kalluri

The paper shows that type-I conventional dendritic cells enhance checkpoint blockade immunotherapy effectiveness in pancreatic cancer when combined with pancreatitis.

bioRxiv · Mar 5, 2023 · PreprintCancer Biology

STAT3 protects HSCs from intrinsic interferon signaling and loss of long-term blood-forming activity

B. Patel, Y. Zhou, R. L. Babcock, F. Ma, M. A. Zal, D. Kumar, Y. B. Medik, L. M. Kahn, J. E. Pineda, E. M. Park, X. Tang, M. G. Raso, T. Zal, K. Clise-Dwyer, F. G. Giancotti, , S. S. Watowich

This study shows that STAT3 is essential for maintaining hematopoietic stem cell function by suppressing interferon signaling and myeloid skewing, and its loss leads to impaired hematopoietic activity.

bioRxiv · Feb 10, 2023 · PreprintImmunology

Tonic interferon restricts pathogenic IL-17-driven inflammatory disease via balancing the microbiome

I. J. Marie, L. Brambilla, D. Azzouz, Z. Chen, G. V. Baracho, A. Arnett, H. S. Li, W. Liu, L. Cimmino, P. Chattopadhyay, G. Silverman, S. S. Watowich, B. Khor, D. Levy

This study shows that tonic interferon signaling maintains immune homeostasis by regulating gut microbiota, preventing IL-17-driven inflammation and myeloid hyperplasia in STAT1 KO mice.

bioRxiv · Apr 21, 2021Immunology